Saturn V Capital Management L.P. 13F annual report
Saturn V Capital Management L.P. is an investment fund managing more than $265 billion ran by Douglas Edwards. There are currently 26 companies in Mr. Edwards’s portfolio. The largest investments include Argenx Se and Disc Medicine Inc, together worth $50.3 billion.
$265 billion Assets Under Management (AUM)
As of 7th August 2024, Saturn V Capital Management L.P.’s top holding is 64,196 shares of Argenx Se currently worth over $27.6 billion and making up 10.4% of the portfolio value.
In addition, the fund holds 503,089 shares of Disc Medicine Inc worth $22.7 billion.
The third-largest holding is Crinetics Pharmaceuticals In worth $21.5 billion and the next is Vaxcyte worth $16.3 billion, with 215,680 shares owned.
Currently, Saturn V Capital Management L.P.'s portfolio is worth at least $265 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Saturn V Capital Management L.P.
The Saturn V Capital Management L.P. office and employees reside in Austin, Texas. According to the last 13-F report filed with the SEC, Douglas Edwards serves as the Chief Financial Officer at Saturn V Capital Management L.P..
Recent trades
In the most recent 13F filing, Saturn V Capital Management L.P. revealed that it had opened a new position in
Cargo Therapeutics Inc and bought 856,849 shares worth $14.1 billion.
The investment fund also strengthened its position in Disc Medicine Inc by buying
248,286 additional shares.
This makes their stake in Disc Medicine Inc total 503,089 shares worth $22.7 billion.
On the other hand, there are companies that Saturn V Capital Management L.P. is getting rid of from its portfolio.
Saturn V Capital Management L.P. closed its position in Apellis Pharmaceuticals Inc on 14th August 2024.
It sold the previously owned 71,463 shares for $4.2 billion.
Douglas Edwards also disclosed a decreased stake in Argenx Se by approximately 0.1%.
This leaves the value of the investment at $27.6 billion and 64,196 shares.
One of the smaller hedge funds
The two most similar investment funds to Saturn V Capital Management L.P. are Ribbit Capital Gp Ii and Mccarthy & Cox. They manage $265 billion and $265 billion respectively.
Douglas Edwards investment strategy
Saturn V Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 59.2% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
4% of the total holdings value.
On the other hand, small-cap stocks make up only 3.8% of the portfolio.
The average market cap of the portfolio companies is close to $2.92 billion.
The complete list of Saturn V Capital Management L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Argenx Se |
2.14%
64,196
|
$27,606,848,000 | 10.43% |
| Disc Medicine Inc |
97.44%
503,089
|
$22,674,221,000 | 8.57% |
| Crinetics Pharmaceuticals In |
27.34%
479,681
|
$21,484,912,000 | 8.12% |
| Vaxcyte, Inc. |
16.47%
215,680
|
$16,285,997,000 | 6.15% |
| Ascendis Pharma A/S |
9.47%
113,224
|
$15,441,489,000 | 5.83% |
| Cytokinetics Inc |
3.16%
272,036
|
$14,738,910,000 | 5.57% |
| Biomarin Pharmaceutical Inc. |
49.84%
178,589
|
$14,703,232,000 | 5.56% |
| Cogent Biosciences, Inc. |
4.95%
1,673,919
|
$14,111,137,000 | 5.33% |
| Cargo Therapeutics Inc |
Opened
856,849
|
$14,069,461,000 | 5.32% |
| KalVista Pharmaceuticals Inc |
21.74%
1,128,478
|
$13,293,471,000 | 5.02% |
| Celcuity Inc |
Opened
760,941
|
$12,464,214,000 | 4.71% |
| Merus N.V |
56.25%
164,773
|
$9,749,618,000 | 3.68% |
| Syndax Pharmaceuticals Inc |
5.44%
419,654
|
$8,615,497,000 | 3.26% |
| Abivax Sa |
0.77%
627,760
|
$8,298,987,000 | 3.14% |
| Ironwood Pharmaceuticals Inc |
17.88%
1,113,824
|
$7,262,132,000 | 2.74% |
| Amicus Therapeutics Inc |
20.58%
713,536
|
$7,078,277,000 | 2.67% |
| AnaptysBio Inc |
57.41%
249,609
|
$6,255,202,000 | 2.36% |
| Phathom Pharmaceuticals Inc |
18.43%
593,306
|
$6,111,052,000 | 2.31% |
| iTeos Therapeutics, Inc. |
5.08%
367,429
|
$5,452,646,000 | 2.06% |
| Inozyme Pharma, Inc. |
Opened
1,140,310
|
$5,085,783,000 | 1.92% |
| Apellis Pharmaceuticals Inc |
Closed
71,463
|
$4,200,595,000 | |
| Neumora Therapeutics Inc. |
Opened
390,084
|
$3,834,526,000 | 1.45% |
| Geron Corp. |
Closed
1,123,995
|
$3,709,184,000 | |
| Enliven Therapeutics Inc |
Opened
152,178
|
$3,556,400,000 | 1.34% |
| Cabaletta Bio Inc |
Closed
173,173
|
$2,954,331,000 | |
| Longboard Pharmaceuticals In |
Opened
71,442
|
$1,931,077,000 | 0.73% |
| Rapport Therapeutics Inc |
Opened
70,000
|
$1,628,200,000 | 0.62% |
| Morphic Hldg Inc |
44.34%
47,660
|
$1,623,776,000 | 0.61% |
| Contineum Therapeutics Inc |
Opened
72,831
|
$1,282,554,000 | 0.48% |
| No transactions found | |||
| Showing first 500 out of 29 holdings | |||
Hedge funds similar to Saturn V Capital Management L.P.
- Coyle Counsel
- Great Oak Capital Partners
- One Fin Capital Management L.P.
- Linden Advisors L.P.
- Phraction Management
- Brown University
- Mccarthy & Cox
- Ribbit Capital Gp Ii
- Fiduciary Planning
- Prospect Capital Advisors
- Promethos Capital
- Concord Investment Counsel
- Valley Forge Investment Consultants Inc Adv
- White Pine Capital